BRCA1 and colorectal carcinoma: Our pathway analysis using Ingenuity Variant Analysis (IVA) revealed that the inferred activity of BRCA1/2 mutations was loss of function and that the BRCA-DNA damage pathway has been altered significantly in more than 65% of the CRC patients compared to the healthy controls (P-value = 4.25E-16).